BRCA2 and breast cancer: Studies have shown that tumors with BRCA2 mutations demonstrate enhanced sensitivity to DNA-damaging chemotherapy through failure to repair double-strand breaks, with overall response rates exceeding those of sporadic breast cancers treated with anthracycline-based regimens [43].